Treatment with low-dose dh404 restored NRF2 activity and expression of its target genes, attenuated activation of NF-κB and fibrotic pathways, and reduced glomerulosclerosis, interstitial fibrosis, and inflammation. This evidence concerns the gene NFKB1 and glomerulosclerosis.